Shots:

• In Oct’2019 United Healthcare plans utilizing Amgen’s Mvasi (biosimilar- bevacizumab) and Kanjinti (biosimilar- trastuzumab) as preferred products for commercial and community plans (but not Medicare Advantage)- while with no longer preference to reference products Avastin and Herceptin  
• Additionally- on Oct 1- 2019 Sandoz’s Zarxio (biosimilar filgrastim) will be listed as preferred product before use of follow-on filgrastim (Granix)- brand-name filgrastim (Neupogen)- or Pfizer’s biosimilar product (Nivestym) and also preferred Celltrion & Pfizer’s biosimilar (Inflectra)- and Samsung Bioepis & Merck’s biosimilar (Renflexis) over brand name infliximab (Remicade)
• Genentech’s Avastin (bevacizumab) is a mAb targeted to treat multiple indications of cancer and Herceptin (trastuzumab) is a mAb can be administered as an IV or as a SC infusion- binds to HER2 receptors present on the surface of HER2-positive tumor cells

Click here to read full press release/ article | Ref: United Healthcare | Image: BioWorld